Notably, the SAM cycle inhibitor 3‐deazaneplanocin A (DZNep), an inhibitor of AHCY, has especially potent and selective antiviral efficacy against SARS‐CoV‐2 in in vitro, in ex vivo, and in a mouse infection model. This evidence concerns the gene AHCY and infection.